Pharming « Terug naar discussie overzicht

Op naar 1 euro

15.953 Posts, Pagina: « 1 2 3 4 5 6 ... 345 346 347 348 349 350 351 352 353 354 355 ... 794 795 796 797 798 » | Laatste

Omlaag ↓

[verwijderd] 15 december 2015 09:34

Geen instappers dus weer een dag van rust

[verwijderd] 15 december 2015 09:37

0.271 blok is weg zal het dan toch?

[verwijderd] 15 december 2015 11:00

quote:
husa schreef op 15 december 2015 09:16:
in usa wordt een renteverhoging verwacht daarop reageren de beurzen nu negatief.wat pharming betreft is het eerst overwinteren maar daarna komt de lente. alle vooruitzichten zijn goed en begin maart zullen we een serieuze koersopstoot krijgen op basis van goede cijfers en misschien ook al de goedkeuring fase 2. normaal gezien moet dit dan eindelijk enkele grote investeerders aantrekken die de koers zullen blijven ondersteunen. daarna terug in een index geraken. belgische beleggers die na 1 januari willen bijkopen moeten weten dat indien ze binnen de zes maanden verkopen een meerwaarde belasting moeten betalen. dit om gokken te voorkomen ik vind dat een goede maatregel.

Renteverhoging daardoor beurs negatief?.Het is de olieprijs meneer husa ;ff opletten.
Alle vooruitzichten zijn goed voor Pharming,meneer husa?.De omzet komt nog steeds niet op gang.Inkomsten derde kwartaal lager dan tweede kwartaal En daar draait alles om.Maar misschien het vierde kwartaal miljoen of 4?.Zou niet gek zijn.En ik hoop het voor je.

De koers is de weerspiegeling van de verwachting v.w.b. de prestaties van Pharming.Koers was zelfs hoger in de tijd toen er in de VS geen inkomsten waren.Men verwachtte toen dus nogal wat. Nu een beurswaarde van zo'n 110 miljoen.

Het zou aardig zijn als de heer de Vries tijdens de Nieuwjaarsborrel aan zou geven hoeveel inkomsten er in het vierde kwartaal zijn gescoord.Nu moet je wachten tot maart.

[verwijderd] 15 december 2015 13:25

Omzet is weer ruk, staat zo weer onder de 0,27

[verwijderd] 15 december 2015 14:44

Pre opening valeant +6,5%

CW1884 15 december 2015 14:53

quote:
$euri schreef op 15 december 2015 14:44:
Pre opening valeant +6,5%

Valeant Announces New U.S. Fulfillment Agreements With Walgreens; Plans To Further Extend Distribution To Independent Pharmacies

12/15/2015
[/i]Valeant to reduce prices by 10 percent for all dermatological and ophthalmological products distributed through more than 8,000 Walgreens retail outlets as well as additional participating independent pharmacies

Valeant will also distribute certain branded products, that have generics available, in the dermatology, ophthalmology, gastrointestinal and neurology/other therapeutic areas through Walgreens at generic prices; an expected average price decrease of more than 50 percent

Valeant estimates that the price decreases across both programs are expected to provide the healthcare system up to $600 million in annual savings

Fulfillment agreements designed to help enhance patient care through expanded services and lower out-of-pocket expenses[/i]

LAVAL, Quebec and DEERFIELD, Ill., Dec. 15, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant") today announced new fulfillment agreements with Walgreens while indicating it intends to extend this distribution model to additional participating independent retail pharmacies. In conjunction with the fulfillment agreement, Valeant will reduce prices of its branded prescription-based dermatological and ophthalmological products by 10 percent. The reduced pricing will apply to the wholesale list prices of these products and will be phased in over the next six to nine months. This agreement also covers Valeant's over-the-counter product portfolio.

The agreement will enable consumers to conveniently access Valeant's dermatology and ophthalmology products at a lower out-of-pocket cost from more than 8,000 Walgreens U.S. retail pharmacy locations, as well as participating independent retailers. The 20-year agreement takes effect the first quarter of 2016 and will initially cover Valeant's dermatology products – including, most notably, Jublia®, Luzu™, Solodyn®, Retin-A Micro® Gel 0.08%, Onexton™ and Acanya® Gel – and ophthalmology products – including Besivance®, Lotemax®, Alrex®, Prolensa ®, Bepreve® and Zylet®. Valeant and Walgreens hope to expand the relationship to include other therapeutic areas over time.

The agreement is designed to create a more efficient model to help lower costs while ensuring patients have convenient access to the products their doctors prescribe. Patients with commercial insurance can benefit from lower out-of-pocket costs, such as reduced copays, set to be as low as zero for some products initially, and the program will provide convenient access for patients who lack coverage for the products. Because of government regulation, the cost sharing program will not be applicable to patients with government insurance.

Walgreens and Valeant also have entered into a separate agreement under which Valeant will distribute more than 30 branded products, where generics are available, in the dermatology, ophthalmology, gastrointestinal and neurology/other therapeutic areas through Walgreens at generic prices, giving doctors the ability to make the branded product available to patients at generic prices. The reduced pricing for the branded products, which will be available to all patients beginning the second half of 2016, is expected to range from 5 percent to 95 percent, or a weighted average price decrease of more than 50 percent. The agreement covers such products as Aldara®, Tiazac®, and Glumetza®. This program will be available to all patients, including those with government coverage.

Valeant expects the price decreases across both programs, when fully implemented, will provide up to $600 million in annual savings to the healthcare system. This number is derived from calculating the 10 percent reduction in average selling price (ASP) of Valeant's dermatology and ophthalmology brands, multiplied by the actual 2015 volume, plus the estimated 50 percent price reduction in ASP of Valeant's branded products to the current reimbursed generic equivalent at 2015 volumes.

"We have listened to what the marketplace is saying and we've taken positive steps to respond. We are pleased to announce both a strategic fulfillment agreement with Walgreens, as well as a new agreement to offer innovator products at generic prices, which is good for consumers, good for physicians and good for the healthcare system," said J. Michael Pearson, chairman and chief executive officer of Valeant. "Our goal is to create a system that allows prescription medications to be dispensed and insurance claims adjudicated in an efficient manner while allowing physicians to focus their efforts on what matters most: patient care."

"Walgreens is always looking for ways to expand the products and services people want and need, and our agreement with Valeant advances our commitment to creating a patient-led pharmacy experience," said Alex Gourlay, President of Walgreen Co. "In addition to promoting pharmacist-patient interactions to improve care and medication adherence, this agreement creates a new direct distribution model that we believe will help increase efficiency."

The direct distribution model for Valeant's dermatology and ophthalmology products through Walgreens and independent pharmacies is designed to help reduce costs and administrative processes, yielding savings that can benefit patients and the healthcare system. Independently, Walgreens has retained Leavitt Partners, headed by former U.S. Dept. of Health and Human Services (HHS) Secretary and former Utah governor Michael Leavitt, to assess the model and evaluate its benefits to patients and markets to ensure it is delivering value.

Mogelijk hier mee te maken?

[verwijderd] 15 december 2015 14:57

Zou kunnen, nu bijna + 9%
Toch wel wat anders dat dat zielige procentje hier :)

CW1884 15 december 2015 14:58

Valeant To Hold Investor Day On December 16 (Updated)

11/20/2015
Valeant Pharmaceuticals has updated its press release from earlier today, adding further information regarding the time of its Investor Day. The complete, corrected release follows.

Valeant To Hold Investor Day On December 16
LAVAL, Quebec , Nov. 20, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that the Company will be hosting an Investor Day on December 16, 2015 , from 8:00 a.m. ET to 12:30 p.m. ET , where the Company will be providing updated financial guidance, discussing certain business operations and highlighting certain R&D programs.

Conference Call and Webcast Information

The dial-in number to participate on this call is (877) 876-8393, confirmation code 86470820. International callers should dial (973) 200-3961, confirmation code 86470820. A replay will be available following the conclusion of the conference call through December 23, 2015 , and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 86470820.

The webcast and slide presentation will be hosted in the investor relations section of its corporate website at www.valeant.com . Participants should allow approximately five to ten minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com .

Morgen niet vergeten. Misschien ziet er nog wat in het vaatje voor Valeant

[verwijderd] 15 december 2015 14:59

Maar hier is het nog niet echt feest met Pharming nog geen 500.000 stuks verhandelt

[verwijderd] 15 december 2015 15:02

nu net er boven 500.000stuks

[verwijderd] 15 december 2015 15:04

No gmeer ook
www.nasdaq.com/symbol/vrx/real-time

Valeant inks fulfillment deal with Walgreens; shares up 8% premarket
seekingalpha.com/news/2984156-valeant...

[verwijderd] 15 december 2015 15:05

11,2%

[verwijderd] 15 december 2015 15:06

quote:
$euri schreef op 15 december 2015 15:05:
11,2%

Zal mooi zijn als Pharming ook zijn duimpje op stak voor een lift voor waarts.

CW1884 15 december 2015 15:06

quote:
$euri schreef op 15 december 2015 15:05:
11,2%

Helaas heeft het bedrijf uit Leiden hier zo weinig aan.

[verwijderd] 15 december 2015 15:06

12,8, helaas wel cw, net of ze niks met valeant te maken hebben

[verwijderd] 15 december 2015 15:12

De vraag is wel aardig vandaag ?

[verwijderd] 15 december 2015 15:18

14,7%

CW1884 15 december 2015 15:20

quote:
$euri schreef op 15 december 2015 15:06:
12,8, helaas wel cw, net of ze niks met valeant te maken hebben

Zijn inderdaad twee verschillende bedrijven $euri. Wanneer er al wat gaat gebeuren bij Pharming, dan pas na het geweld bij Valeant. Dus afwachten tot ca. 16.30 uur. Wanneer er dan nog steeds niets gebeurd heeft Valeant dus geen invloed op Pharming.

[verwijderd] 15 december 2015 15:21

quote:
$euri schreef op 15 december 2015 15:18:
14,7%

Zal mooi zijn als die Amerikanen nu ook Pharming een zet mee geven.

[verwijderd] 15 december 2015 15:27

Tot morgen denk ik , wordt niks meer

15.953 Posts, Pagina: « 1 2 3 4 5 6 ... 345 346 347 348 349 350 351 352 353 354 355 ... 794 795 796 797 798 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	28 feb 2025 17:35
Koers	0,870
Verschil	-0,020 (-2,25%)
Hoog	0,883
Laag	0,863
Volume	4.024.492
Volume gemiddeld	5.436.894
Volume gisteren	3.180.321

Pharming nieuws meer

20 feb	Pharming heeft bijna 93% van Abliva i...	1
07 feb	Pharming verklaart bod op Abliva onvo...
21 jan	Pharming stemt over nieuwe CEO
21 jan	Pharming presenteert nieuwe CEO
16 jan	Fundlogic verkoopt bijna geheel belan...	4
15 jan	Fundlogic flink groter in Pharming	1
07 jan	DWS meldt groter belang in Pharming
31 dec	Morgan Stanley groter in Pharming
23 dec	CEO: Pharming koopt met KL1333 van Ab...
19 dec	RBC verhoogt koersdoel Pharming fors